Olga Shilova

Dr. Olga Shilova


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
ESEvgeniya Sokolova
Evgeniya Sokolova
GPGalina Proshkina
Galina Proshkina
Olga KutovaOlga Kutova
Olga Kutova
OSOlga Shilova
Olga Shilova
ARAnastasiya Ryabova
Anastasiya Ryabova
SDSergey Deyev
Sergey Deyev

15 December 2019 in Acta Naturae
Verified
Journal Article
Open access
OSOlga Shilova
Olga Shilova
SDS. M. Deyev
S. M. Deyev
Monoclonal antibodies are the classical basis for targeted therapy, but the development of alternative binding proteins has made it possible to use non-immunoglobulin proteins as targeting modules. The advantages of DARPins, scaffold proteins based on ankyrin repeats, over antibodies are as follows: small size, stability over a wide range of temperatures and pH values, low aggregation tendency, and ease of production in heterologous expression systems. The differences in the structure of the paratope of DARPin and antibodies broaden the spectrum of target molecules, while the ease of creating hybrid fusion proteins allows one to obtain bispecific and multivalent constructs. In this article, we summarize recent data on the development of therapeutic and imaging compounds based on DARPins.

30 August 2017 in Cytometry Part A
Verified
Journal Article
Open access
PDF file
OSOlga Shilova
Olga Shilova
ESEvgeny S. Shilov
Evgeny S. Shilov
SDSergey M. Deyev
Sergey M. Deyev
Controlling background fluorescence remains an important challenge in flow cytometry, as autofluorescence can interfere with the detection of chromophores. Furthermore, experimental procedures can also affect cellular fluorescence in certain regions of the emission spectrum. In this work, the effects of fixation, permeabilization, and heating on cellular autofluorescence are analyzed in various spectral regions, along with the influence of trypan blue as a quenching dye for these treatments. The impact of these procedures on the staining of SK‐BR‐3 cells with a dim green fluorophore, a miniSOG (mini Singlet Oxygen Generator) flavoprotein in the form of the recombinant protein DARPin‐miniSOG, is also evaluated. The data presented here indicate that fixation of certain types of cells leads to noticeable increase of the autofluorescence. Our results also suggest that trypan blue should be used as an autofluorescence quencher only with bright green emitters since it interferes with the fluorescent signal in a longer‐wavelength region of the spectrum and as a result causes reduction of the signal from dim green fluorescent agents. © 2017 International Society for Advancement of Cytometry

1 November 2015 in Biochimie
Verified
Journal Article
Closed access
GPG.M. Proshkina
G.M. Proshkina
OSOlga Shilova
Olga Shilova
ARA.V. Ryabova
A.V. Ryabova
OSO.A. Stremovskiy
O.A. Stremovskiy
SDSergey Deyev
Sergey Deyev

15 September 2015 in Acta Naturae
Verified
Journal Article
Open access
PDF file
OSOlga Shilova
Olga Shilova
GPG. M. Proshkina
G. M. Proshkina
ELE. N. Lebedenko
E. N. Lebedenko
SDS. M. Deyev
S. M. Deyev
Design and evaluation of new high-affinity protein compounds that can selectively and efficiently destroy human cancer cells are a priority research area in biomedicine. In this study we report on the ability of the recombinant phototoxic protein DARPin-miniSOG to interact with breast adenacarcinoma human cells overexpressing the extracellular domain of human epidermal growth factor receptor 2 (HER2). It was found that the targeted phototoxin DARPin-miniSOG specifically binds to the HER2 with following internalization and slow recycling back to the cell membrane. An insight into the role of DARPin-miniSOG in HER2 internalization could contribute to the treatment of HER2-positive cancer using this phototoxic protein.

Verified
Journal Article
Open access
PDF file
OSOlga Shilova
Olga Shilova
ESElena Shramova
Elena Shramova
GPGalina Proshkina
Galina Proshkina
SDSergey Deyev
Sergey Deyev
Cancer cells frequently overexpress specific surface receptors providing tumor growth and survival which can be used for precise therapy. Targeting cancer cell receptors with protein toxins is an attractive approach widely used in contemporary experimental oncology and preclinical studies. Methods of targeted delivery of toxins to cancer cells, different drug carriers based on nanosized materials (liposomes, nanoparticles, polymers), the most promising designed light-activated toxins, as well as mechanisms of the cytotoxic action of the main natural toxins used in modern experimental oncology, are discussed in this review. The prospects of the combined therapy of tumors based on multimodal nanostructures are also discussed.